Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2006 by Taichung Veterans General Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Ton General Hospital
Information provided by:
Taichung Veterans General Hospital
ClinicalTrials.gov Identifier:
NCT00313066
First received: April 9, 2006
Last updated: NA
Last verified: April 2006
History: No changes posted
  Purpose

Connective tissue growth factor (CTGF) is known to be a fibrogenic cytokine, it could be expressed in various fibrosis diseases. But, recent research showed that CTGF also be considered to be a tumor suppressive gene. The expression of CTGF protein is higher in normal Type I and II alveolar epithelial cells than metastatic tumor cells. CTGF appears to be a suppressor of lung tumor invasion and in metastasis and the decreased CTGF expression in tumor tissues was associated with advanced tumor stage, lymph node metastasis, early postoperative relapse and shorter patient survival.

CTGF can be expressed in many human organs such as heart, brain, placenta, liver, muscle, kidney, peritoneal mesothelial cells and lung but did not known in the pleura. The CTGF protein is present in the peritoneal cavity and is increased during peritonitis. Considering pleural cavity comes from the same origin of mesenchyma with peritoneum, pericardium and fallopian tube, we aim to evaluate whether the CTGF expression increase in the pleurisy patients including the parapneumonic effusion and the TB pleurisy.

The diagnosis of TB pleurisy depends on the effusion TB culture and pleural biopsy. Unfortunately the sensitivity of TB culture was only 20-30%. So most patients must receive invasive pleural biopsy. Adenosine deaminase(ADA) was developed as a screening test but should not be considered an alternative test to culture and biopsy. The sensitivity of ADA might vary from 32%-100% and the cutoff value also vary from 26 to 70 IU/L. We should develop a method to alternate the culture and biopsy . Therefore, our technologist Jao-Jia chu will develop the CTGF ELISA kit for this specific aim. If CGTF might increase expression in pleuritis but decrease in pleural metastasis, it might be a potential method help to differentiate lymphocytic pleural effusion between TB pleurisy and malignancy.


Condition Phase
Tuberculosis
Tuberculous Pleurisy
Malignant Pleural Effusion
Empyema
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Among Tuberculous Pleurisy and Malignant Pleural Effusion Patients

Resource links provided by NLM:


Further study details as provided by Taichung Veterans General Hospital:

Estimated Enrollment: 80
Study Start Date: November 2005
Estimated Study Completion Date: November 2006
Detailed Description:

Connective tissue growth factor (CTGF, also known as CCN2) is a member of the CCN family. Cysteine-rich 61(Cyr61) is known as CCN1, and nephroblastoma over-expressed (Nov, known as CCN3) as well as Wisp-1/elm1( CCN4),Wisp-2/rCop1(CCN5), and Wisp-3 (CCN6)1. The CTGF is a secretory growth factor that bind with integrins on the cell surface and was first identified as a mitogen isolated from the medium of human umbilical vein endothelial cells2. CTGF can be expressed in many human organs such as heart, brain, placenta, liver, muscle, kidney, and lung and may have many biologic functions3. CTGF stimulate the proliferation of fibroblast and vascular endothelial cells. The level of CTGF protein is increased in patients with various fibrotic human disease including renal failure, hepatic fibrosis in biliary atresia, systemic scleroderma and vascular atherosclerosis4.

Recent research revealed the expression of CTGF protein was high in the normal lung epithelium and moderate to high in stage I lung adenocarcinoma cells5. But the expression of CTGF was reduced in low grade metastatic respiratory epithelial tumor cells. The CTGF expression was associated with the suppression of human lung cancer cell metastasis in a mouse model and the reduced CTGF expression was also associated with clinical metastasis and patient survival5. The expression of CTGF protein was statistically significantly higher in normal lung type I and II epithelial cells than in the majority of metastatic adenocarcinoma specimens revealed that the level of CTGF protein decreases during clinical disease when cells acquire the ability to grow at metastatic site6. CTGF appears to be a suppressor of lung tumor invasion and metastasis and the decreased CTGF expression in tumor tissues was associated with advanced tumor stage, lymph node metastasis, early postoperative relapse, and shorter patient survival. Connective tissue growth factor acts as an independent prognostic marker in colorectal cancer and giomas and inhibits metastasis7,8

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- patients with pleural effusion

Exclusion Criteria:

  • HIV infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00313066

Contacts
Contact: Shen Gwan Han, MD +886-4-23592525 ext 3217 911B@vghtc.gov.tw

Locations
China, Taiwan
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital Recruiting
Taichung, Taiwan, China, 407
Contact: Shen Gwan Han, MD    +886-4-23592525 ext 3217    911B@vghtc.gov.tw   
Principal Investigator: Shen Gwan Han, MD         
Sponsors and Collaborators
Taichung Veterans General Hospital
Ton General Hospital
Investigators
Principal Investigator: Shen Gwan Han, MD Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00313066     History of Changes
Other Study ID Numbers: 940513/C05092
Study First Received: April 9, 2006
Last Updated: April 9, 2006
Health Authority: Taiwan: Department of Health

Keywords provided by Taichung Veterans General Hospital:
CTGF
fibrogenic cytokine
FGF
pleural fibrosis

Additional relevant MeSH terms:
Pleural Effusion
Pleural Effusion, Malignant
Empyema
Pleurisy
Tuberculosis
Tuberculosis, Pleural
Suppuration
Infection
Inflammation
Pathologic Processes
Pleural Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Pleural Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on August 21, 2014